| Human medicines European public assessment report (EPAR): Carmustine Obvius, carmustine, Hodgkin Disease;Lymphoma, Non-Hodgkin, Date of authorisation: 18/07/2018, Revision: 7, Status: Authorised | | Human medicines European public assessment report (EPAR): Carmustine Obvius, carmustine, Hodgkin Disease;Lymphoma, Non-Hodgkin, Date of authorisation: 18/07/2018, Revision: 7, Status: Authorised |
|
| Ontwikkelingen Levosert | | De werkgroep Anticonceptie heeft contact gehad met de fabrikant van de Levosert en we delen graag de uitkomsten hiervan. |
|
|